Please assess the completion status of the following clinical trial:

Trial Title: the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 20 years of age or older at enrollment who are able to visit~2. Patients with chronic stable angina who have severe coronary stenosis wich require PCI.~3. Patients who have at least one coronary plaque (≧ 500μm in thickness or % plaque of 20% or more) at the non-culprit vessels.~4. Patients with hyperuricemia, who have a serum uric acid level \>7.0mg/dL within 2 months prior to enrollement.~5. Patients who personally given written informed consent to participate in this study.~Exclusion Criteria:~1. Patients who had undergone previous PCI for the lesion under investigation.~2. Patients with gouty tophus, or patients with subjective symptoms of gouty arthritis within 1 year prior to enrollment.~3. Patients with a previous history of hypersensitivity to febuxostat or allopurinol.~4. Patients with serious kidney disease, Acute kidney disease, nephrotic syndrome, dialysis patients, kidney transplant patients, eGFR \< 30 mL/min/1.73m2, etc.~5. Patients with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) 2 or more times the upper limit of normal.~6. Patients on any of the following medications at enrollment Mercaptopurine hydrate, azathioprine, vidarabine, or didanosine.~7. Patients who receive any of the following medications for the treatment of hyperuricemia within 1 month prior to enrollment Allopurinol, benzbromarone, probenecid, bucolome, topiroxostat, or febuxostat.~8. Patients otherwise judged by the principal or sub-investigator to be unsuitable for the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non febuxostat treatment group (Type: NO_INTERVENTION): No febuxostat treatment
- Febuxostat treatment group (Type: EXPERIMENTAL): once daily after breakfast

Based on this trial design, predict the completion outcome and termination type (if applicable).